ライフサイエンスコーパス: Pharma

1 y qualified vaccine developed outside of big pharma.

2 ncer Foundation, SIAK Switzerland, and Bayer Pharma.

3 h Cancer Foundation; SIAK Switzerland; Bayer Pharma.

4 land) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular age-relat

5 sted the effect of everolimus (RAD, Novartis Pharma AG, Basel, Switzerland) on human PTLD-derived cel

6 Roche Pharma AG, Mundipharma, German Federal Ministry of Educa

7 hylated pectin) in development by Archimedes Pharma and CriticalSorb(TM) (polyglycol mono- and dieste

8 on February 11-16 and sponsored by Astellas Pharma and Regulus Therapeutics.

9 a), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisations in participa

10 a), Servier, GlaxoSmithKline, Novartis, King Pharma, and national or local organisations in participa

11 In contrast to our report on Novartis Pharma APP23 Tg mice, which maintain high levels of solu

12 Research Council GLOBVAC Program and Bionor Pharma ASA.

13 c, and gadolinium-enhanced (Magnevist; Bayer Pharma, Berlin, Germany) magnetic resonance (MR) imaging

14 g pro-drugs of propofol such as Aquavan (MGI Pharma, Bloomington, Minnesota, USA) and novel 'soft-dru

15 ct of lurasidone (Latuda; Dainippon Sumitomo Pharma Co. Ltd., Tokyo, Japan), a newly approved atypica

16 stigate short-term efficacy, pharmacokinetic/pharma- codynamic (PK/PD) relations, and safety of ICL67

17 compounds with better properties than do big pharma companies and universities.

18 in-cleaving enzyme 1 (BACE-1), with many big pharma companies expending great resources in the search

19 plifies the interest of multi-billion dollar pharma companies worldwide for further developments of S

20 Here, experts from a large pharma company and a biotech firm provide their perspect

21 shed parallel high throughput screening of a pharma compound collection against kinetoplastids.

22 e natural products-based method of potential pharma discovery is much augmented by the capacities of

23 Orion Corporation Orion Pharma, Endo Pharmaceuticals Inc.

24 Astellas Pharma Global Development, Basilea Pharmaceutica Interna

25 n LLC, King of Prussia, PA, USA; and Centeon Pharma GmbH, Marburg, Germany) is marketed in Europe, So

26 ty (ADMET) data shared across multiple major pharma has been performed.

27 Pharma has responded by embarking on a range of initiati

28 Pharma has responded by embarking on a range of initiati

29 For a range of potential products (fuel to pharma), high lipid productivity strains are required to

30 rces available to scientists working in "big pharma." High costs include those associated with high-t

31 Indeed, the power of "Big Pharma" in many medical fields including transplantation

32 nd sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in who

33 Astellas Pharma, Inc and Medivation, Inc.

34 This has caused considerable change in large pharma including how medicinal chemists are trained.

35 preparation (VSL#3, 9 x 10(11) bacteria; CD Pharma India Private Limited, New Delhi, India) (n = 66)

36 olvents compatible with further uses in food/pharma industries demonstrated that RSM constitutes a po

37 penta decalactone (azone)) developed by CPEX Pharma, Intravail (alkylsaccharides) developed by Aegis

38 eview is highly pertinent at a time when big pharma is desperately trying to escape flatland drugs.

39 s Ltd), Chisys based on chitosan (Archimedes Pharma Ltd) and Intravail based on alkylsaccharides (Aeg

40 ther antioxidant therapy (Antox version 1.2, Pharma Nord, Morpeth, UK) or matched placebo (2 tablets,

41 Many major Pharma now have R&D programmes in this area and in 2013

42 ults indicate the potential of cloudberry in pharma or health food applications.

43 al properties were identified from a Zealand Pharma peptide library using pharmaceutical profiling, e

44 re-S2) recombinant vaccine (Hepacare; Medeva Pharma Plc, Speke, UK).

45 enges facing the pharmaceutical industry and Pharma's responses to address these challenges.

46 enges facing the pharmaceutical industry and Pharma's responses, focusing on the industry's changing

47 (Enzon Pharmaceuticals, Piscataway, NJ; Skye Pharma, San Diego, CA), an intrathecal (IT) preparation

48 the lead on the establishment of a 'virtual pharma' structure, through which researchers will partne

49 CIFRE grant from the French Government, HRA-Pharma, the French Ministry of Education and Research, a

50 Because of the growth of "Big Pharma," the relationship between academia and industry

51 ficacy, are critical for partnering with Big Pharma to produce novel therapeutics.

52 The decision of big Pharma to reduce investment from the Neurosciences has h

53 ancer Research UK, Janssen-Cilag, and Chugai Pharma UK.

54 target, at least in the view of many in 'Big Pharma,' 'undruggable' for this indication.